These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27258224)

  • 21. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deciphering Genetic Variants of Warfarin Metabolism in Children With Ventricular Assist Devices.
    Baban A; Iodice FG; Di Molfetta A; Cicenia M; Rizzo C; Agolini E; Drago F; Novelli A; Di Chiara L; Testa G; Amodeo A
    Pediatr Cardiol; 2021 Jun; 42(5):1082-1087. PubMed ID: 33837838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
    Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
    Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
    Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China.
    Lin G; Yi L; Zhang K; Sun Y; Wang L; Zhang R; Xie J; Li J
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):129-34. PubMed ID: 25815675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
    Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A
    J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
    Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
    [No Abstract]   [Full Text] [Related]  

  • 31. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
    Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
    Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
    Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
    Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
    Stergiopoulos K; Brown DL
    JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
    Schapkaitz E; Sithole J
    J Vasc Nurs; 2017 Mar; 35(1):27-30. PubMed ID: 28224948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.